Amicus Therapeutics

Last updated
Amicus Therapeutics, Inc.
Company type Public
Nasdaq:  FOLD
Russell 2000 Component
Industry Biotechnology
FoundedFebruary 4, 2002;22 years ago (2002-02-04) [1] : 28 
Headquarters
Philadelphia, Pennsylvania
,
United States
Key people
Revenue
  • Increase2.svg $91,245,000 (2018)
  • Increase2.svg $36,930,000 (2017)
  • Increase2.svg ($328,777,000) (2018)
  • Decrease2.svg ($441,985,000) (2017)
  • Increase2.svg ($349,089,000) (2018)
  • Decrease2.svg ($449,121,000) (2017)
Total assets
  • Increase2.svg $789,951,000 (2018)
  • Decrease2.svg $627,024,000 (2017)
Total equity
  • Decrease2.svg $342,912,000 (2018)
  • Decrease2.svg $352,850,000 (2017)
Number of employees
508 (31 Dec 2018) [1] : 28 
Website www.amicusrx.com
Footnotes /references
[1] [2]

Amicus Therapeutics, Inc. is a public American biopharmaceutical company based in Philadelphia, PA. [3] The company went public in 2007 under the NASDAQ trading symbol FOLD. [4] This followed a 2006 planned offering and subsequent withdrawal, which would have established the trading symbol as AMTX [5] [6] Prior to their IPO, Amicus was funded by a variety of venture capital firms including Radius Ventures, Canaan Partners and New Enterprise Associates. [7]

History

The therapeutic focus of Amicus is on rare and orphan diseases, particularly disorders collectively called lysosomal storage disorders. [8] : 2  The company has focused on pharmacological chaperones and enzyme replacement therapy. [8] : 2, 18  [9] : 95 

In 2008, the company expanded from its single site in New Jersey to a second research site in San Diego. [10]

In late 2009, the company faced a major financial setback with the termination of a multi-year collaboration agreement with Shire for its lead compound, migalastat, and two other products. [11] : 24  Amicus cut 20% of its workforce. [11] : 24 

The next year, the company signed an exclusive license agreement with GlaxoSmithKline for migalastat; GSK paid $60 million in upfront and equity payments while promising up to $170 million to help develop their products, [12] GSK terminated the arrangement in 2013. [12]

In November 2013, Amicus acquired competitor Callidus Biopharma for its enzyme replacement therapy treatment for Pompe disease. [8] : 3, 12 

In September 2015, the company acquired Scioderm for $229 million in cash and stock, with potentially $618 million more in biodollars. Scioderm had a drug in Phase III trials for epidermolysis bullosa; additionally, if the drug was approved the FDA would give its owner a priority review voucher, which itself can be sold to another company. [13] That drug failed its Phase III trial in 2017 and Amicus abandoned it. It had paid out around half of the milestones to Scioderm's shareholders prior to closing down the program. [14]

Also in September 2015, Amicus announced that it would submit a new drug application (NDA) for accelerated approval of migalastat to the FDA by the end of 2015. [15] An FDA committee recommended approval in April 2016, but the FDA rejected the application in November for having insufficient data in November 2016. [16] The drug was approved in the European Union in May 2016. [17]

In 2016 Amicus acquired MiaMed which was working on drugs to treat CDKL5 deficiency; Amicus paid $1.8M in cash and around $4.7M in stock, with $83M in biodollars. [18]

After Scott Gottlieb became FDA commissioner in 2017, the CEO of Amicus began lobbying him directly for the FDA to accept the NDA and in February 2018 the FDA accepted it and promised a response by August 2018. [19]

In September 2018, Amicus announced that it had acquired Celenex, which had ten early stage gene therapies. Amicus paid $100 million upfront and could pay an additional $352 million if developmental milestones are achieved. [20]

Related Research Articles

Sanofi S.A. is a French multinational pharmaceutical and healthcare company headquartered in Paris, France. The corporation was established in 1973 and merged with Synthélabo in 1999 to form Sanofi-Synthélabo. In 2004, Sanofi-Synthélabo merged with Aventis and renamed to Sanofi-Aventis, which were each the product of several previous mergers. It changed its name back to Sanofi in May 2011. The company is a component of the Euro Stoxx 50 stock market index. In 2023, the company’s seat in Forbes Global 2000 was 89.

<span class="mw-page-title-main">Fabry disease</span> Rare human genetic lysosomal storage disorder

Fabry disease, also known as Anderson–Fabry disease, is a rare genetic disease that can affect many parts of the body, including the kidneys, heart, brain, and skin. Fabry disease is one of a group of conditions known as lysosomal storage diseases. The genetic mutation that causes Fabry disease interferes with the function of an enzyme that processes biomolecules known as sphingolipids, leading to these substances building up in the walls of blood vessels and other organs. It is inherited in an X-linked manner.

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

Neurocrine Biosciences, Inc. is an American biopharmaceutical company founded in 1992. It is headquartered in San Diego, California, and led by CEO Kevin Gorman. Neurocrine develops treatments for neurological and endocrine-related diseases and disorders. In 2017, the company's drug valbenazine (Ingrezza) was approved in the US to treat adults with tardive dyskinesia (TD).

Priority review is a program of the United States Food and Drug Administration (FDA) to expedite the review process for drugs that are expected to have a particularly great impact on the treatment of a disease. The priority review voucher program is a program that grants a voucher for priority review to a drug developer as an incentive to develop treatments for disease indications with limited profitability.

Sirtris Pharmaceuticals, Inc. was a biotechnology company based in Cambridge, MA that developed therapies for type 2 diabetes, cancer, and other diseases. Conceived in 2004 by Harvard University biologist David Sinclair and Andrew Perlman, and founded that year by Sinclair and Perlman, along with Christoph Westphal, Richard Aldrich, Richard Pops, and Paul Schimmel, the company was focused on developing Sinclair's research into activators of sirtuins, work that began in the laboratory of Leonard P. Guarente where Sinclair worked as a post-doc before starting his own lab.

Christoph Westphal is an American biomedical businessman.

<span class="mw-page-title-main">Intepirdine</span> Chemical compound

Intepirdine (INN; developmental codes SB-742457, RVT-101) is a selective 5-HT6 receptor antagonist with potential cognition, memory, and learning-enhancing effects. It was under development by GlaxoSmithKline for the treatment of Alzheimer's disease and demonstrated some preliminary efficacy in phase II clinical trials. GSK chose not to continue development and sold the rights to Axovant Sciences for $5 million in December 2014.

<span class="mw-page-title-main">Santaris Pharma</span> Biopharmaceutical company founded in Denmark

Santaris Pharma A/S was a biopharmaceutical company founded in 2003 in Copenhagen, Denmark. The company also had a branch in San Diego, California that opened in 2009. Created by a merger between Cureon and Pantheco, Santaris developed RNA-targeted medicines using a Locked Nucleic Acid (LNA) Drug Platform and Drug Development Engine.

GTx, Inc. was a pharmaceutical company working on drugs in the selective estrogen receptor modulator (SERM) and selective androgen receptor modulator (SARM) classes. Its drugs in development included enobosarm (ostarine) and GTx-758.

Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts. In 2016, Forbes included the company on its "100 Most Innovative Growth Companies" list.

<span class="mw-page-title-main">Marathon Pharmaceuticals</span> Former U.S. rare disease drug company

Marathon Pharmaceuticals LLC was a privately held biopharmaceuticals company focused on drugs for people with rare diseases. The Illinois-based company developed and manufactured therapeutics and brought them to market. It employed 100 people in four global locations. In 2017, PTC Therapeutics acquired rights to Marathon Pharmaceuticals' drug Emflaza (deflazacort) for $140 million after criticism about their plan to sell the drug at a list price of $89,000 per year to sufferers despite the fact that the same drug was available in Canada and the UK for around $1,000 per year.

Catalyst Pharmaceuticals, Inc. is a biopharmaceutical company based in Coral Gables, Florida, United States. The company develops medicines for rare diseases, including the phosphate salt of amifampridine for the treatment of Lambert–Eaton myasthenic syndrome (LEMS). The drug is referred to under the trade name Firdapse, which was approved by the FDA for approved use in children 6 years and older with LEMS in addition to the prior approval for use in adults with LEMS on November 28, 2018. Firdapse commercially launched in January 2019.

Scioderm, acquired by Amicus Therapeutics in 2015, was a rare disease company focused on developing a treatment for Epidermolysis Bullosa (EB), a rare genetic disease characterized by extremely fragile skin and recurrent blister formation. There are currently no approved therapies for EB. Scioderm was developing a topical treatment known as SD-101, or Zorblisa, aimed at triggering wound reduction and closure, and a reduction in body surface area coverage of blisters and lesions.

<span class="mw-page-title-main">Henri Termeer</span>

Henri A. Termeer was a Dutch biotechnology executive and entrepreneur who is considered a pioneer in corporate strategy in the biotechnology industry for his tenure as CEO at Genzyme. Termeer created a business model adopted by many others in the biotech industry by garnering steep prices— mainly from insurers and government payers— for therapies for rare genetic disorders known as orphan diseases that mainly affect children. Genzyme uses biological processes to manufacture drugs that are not easily copied by generic-drug makers. The drugs are also protected by orphan drug acts in various countries which provides extensive protection from competition and ensures coverage by publicly funded insurers. As CEO of Genzyme from 1981 to 2011, he developed corporate strategies for growth including optimizing institutional embeddedness nurturing vast networks of influential groups and clusters: doctors, private equity, patient-groups, insurance, healthcare umbrella organizations, state and local government, and alumni. Termeer was "connected to 311 board members in 17 different organizations across 20 different industries" He has the legacy of being the "longest-serving CEO in the biotechnology industry.

<span class="mw-page-title-main">Ionis Pharmaceuticals</span> Biotechnology company

Ionis Pharmaceuticals, Inc. is a biotechnology company based in Carlsbad, California, that specializes in discovering and developing RNA-targeted therapeutics. The company has three commercially approved medicines: Spinraza (Nusinersen), Tegsedi (Inotersen), and Waylivra (Volanesorsen), and has four drugs in pivotal studies: tominersen for Huntington's disease, tofersen for SOD1-ALS, AKCEA-APO(a)-LRx for cardiovascular disease, and AKCEA-TTR-LRx for all forms of TTR amyloidosis.

<span class="mw-page-title-main">Migalastat</span> Chemical compound

Migalastat, sold under the brand name Galafold, is a medication for the treatment of Fabry disease, a rare genetic disorder. It was developed by Amicus Therapeutics. The US Food and Drug Administration (FDA) granted it orphan drug status in 2004, and the European Commission followed in 2006. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) granted the drug a marketing approval under the name Galafold in May 2016.

<span class="mw-page-title-main">Intellia Therapeutics</span> American biotechnology company

Intellia Therapeutics, Inc. is an American clinical-stage biotechnology company focused on developing novel, potentially curative therapeutics leveraging CRISPR-based technologies. The company's in vivo programs use intravenously administered CRISPR as the therapy, in which the company's proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. Intellia's ex vivo programs use CRISPR to create the therapy by using engineered human cells to treat cancer and autoimmune diseases.

<span class="mw-page-title-main">Ultragenyx</span> American biopharmaceutical company

Ultragenyx Pharmaceutical Inc. is an American biopharmaceutical company involved in the research and development of novel products for treatment of rare and ultra-rare genetic diseases for which there are typically no approved treatments and high unmet medical need. The company works with multiple drug modalities including biologics, small molecule, gene therapies, and ASO and mRNAs in the disease categories of bone, endocrine, metabolic, muscle and CNS diseases.

<span class="mw-page-title-main">CRISPR Therapeutics</span> Swiss-American biotechnology company

CRISPR Therapeutics AG is a Swiss–American biotechnology company headquartered in Zug, Switzerland. It was one of the first companies formed to utilize the CRISPR gene editing platform to develop medicines for the treatment of various rare and common diseases. The company has approximately 500 employees and has offices in Zug, Switzerland, Boston, Massachusetts, San Francisco, California and London, United Kingdom. Its manufacturing facility in Framingham, Massachusetts won the Facilities of the Year Award (FOYA) award in 2022. The company’s lead program, exagamglogene autotemcel, or exa-cel, was granted regulatory approval by the US Food and Drug Administration (FDA) in December 2023.

References

  1. 1 2 3 "Form 10-K: Amicus Therapeutics, Inc". EDGAR . USSEC. 2018. p. 61. Retrieved 2024-03-04.
  2. ↑ "Amicus Leader, BIO Board Member John Crowley Named Trade Group's New CEO". MedCity News. Dec 5, 2023. Retrieved 2024-03-04.
  3. ↑ "Amicus Corporate Headquarters".
  4. ↑ "Amicus Therapeutics IPO raises $75 mln, in range". Reuters. 30 May 2007.
  5. ↑ Gelsi, Steve (17 May 2006). "Amicus Therapeutics files $86M IPO". MarketWatch .
  6. ↑ Moyer, Liz (16 Aug 2006). "IPOs Head For The Exits". Forbes . There have been five withdrawn IPOs so far this month, including ... Amicus Therapeutics.
  7. ↑ Rubin, Evelyn (18 May 2006). "Amicus IPO: A Very Risky Prospect (AMTX)". Seeking Alpha .
  8. 1 2 3 "Form 10-K: Amicus Therapeutics, Inc". EDGAR . USSEC. 2014.
  9. ↑ Williams, Cory (2014). "Chapter 4. Treating Rare Diseases: Business Model for Orphan Drug Development". In Pryde, David C.; Palmer, Michael J. (eds.). Orphan Drugs and Rare Diseases. Royal Society of Chemistry. ISBN   9781849738064.
  10. ↑ Staff (1 Oct 2008). "Amicus Therapeutics Opens Research Facility in San Diego". Biotech Week . United States. Archived from the original on 24 September 2015.
  11. 1 2 "Form 10-Q: Amicus Therapeutics, Inc". EDGAR . USSEC. 30 Sep 2009.
  12. 1 2 Carroll, John (20 Nov 2013). "GlaxoSmithKline politely dumps $230M Fabry drug deal with Amicus". FierceBiotech.
  13. ↑ Fidler, Ben (31 August 2015). "Xconomy: With $229M Deal, Amicus Gets a New Drug And Perhaps a Voucher". Xconomy.
  14. ↑ Taylor, Phil (September 13, 2017). "Amicus ditches skin disorder drug after late-stage failure". FierceBiotech.
  15. ↑ "Amicus Therapeutics Plans to Submit NDA for Migalastat for Fabry Disease Following Positive Pre-NDA Meeting With FDA". Drugs.com. 15 September 2015.
  16. ↑ Adams, Ben (November 29, 2016). "FDA rejects quick Amicus Fabry drug read-through, new data not expected till 2019". FierceBiotech.
  17. ↑ "Amicus Therapeutics Announces European Commission Approval for Galafold (Migalastat) in Patients with Fabry Disease in European Union". GlobeNewswire. 31 May 2016.
  18. ↑ Adams, Ben (July 7, 2016). "Amicus spends $90M on MiaMed; gains rare disease preclinical program". FierceBiotech.
  19. ↑ Carroll, John (February 12, 2018). "Once rejected, FDA now rolls out a short red carpet for Amicus' migalastat". Endpoints.
  20. ↑ Herper, Matthew. "A $100 Million Biotech Deal Is Also A Tale Of Two Executives Facing Their Kids' Deadly Diseases". Forbes. Retrieved 2018-09-24.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.